Skip to Content Contact Us
ABOUT

ABOUT GOLDMAN BIO

Personalized medicine

Goldman Bio specializes in the development, integration and commercialization of Israeli Life Science technologies, with emphasis on the field of personalized medicine and focusing on cancer.

The field of personalized medicine is emerging as the future of medical treatment. This approach offers new solutions to medical problems and innovative ways to implement existing solutions.

The nature of  the Goldman Bio’s portfolio companies, already dealing with different aspects of personalized medicine (from diagnostics to health care technologies) creates a network of companies with complementary technologies. The Group’s management team, its colleagues, partners and advisors have extensive and proven experience, and possess the combined ability to identify and select breakthrough technologies in the Group’s specialized fields and develop them into valuable commercial assets.

This expertise and specialization have enabled the Group to establish a powerful and proficient infrastructure for the development, integration and commercialization of Israeli cancer research technologies whilst achieving significant economic value on behalf of our stakeholders.

 

our vision

Goldman Bio’s vision is to provide a technology transfer infrastructure for Israeli technologies in the fields of Life Sciences and Personalized Medicine.

To achieve this vision, we have developed a unique structured management methodology that identifies and promotes promising technologies from concept to commercialization within the group’s active structure.

 

 

development

Goldman Bio maintains close contact and has entered into a number of cooperation and development agreements with academic institutions. Amongst the prerequisites for choosing a technology: leading international researchers, an appropriate field of activity, a real market need, and an analysis indicating that the group is capable of commercializing the technology in the short to medium term.

integration

The group holds important advantages with regard to its activities in the field of personalized medicine. The Group specializes in affiliating academia with the private sector and has created a network of companies with complementary technologies.

commercialization

The academic researchers, together with the members of the scientific advisory boards, provide unique understanding and expertise that enables the Group to benefit commercially from their R&D whilst identifying and gaining access at an early stage to additional technologies and business opportunities.

OUR LEADERSHIP

gil pogozelich
Gil Pogozelich, Ph.D General Partner
דרור נגל
Mr. Dror Nagel Chairman
עידו וולף Copy1
Ido Wolf, Ph.D Advisory Board Member
פרופ רפאל קטן Copy1
Rephael Katan, Ph.D Advisory Board Member
Back top top